Age 0 3 0 3 B-age
≥ 4 5 4 5 O
18 6 8 6 8 B-lower_bound
years 9 14 9 14 I-lower_bound

Histological 0 12 15 27 O
or 13 15 28 30 O
cytological 16 27 31 42 O
documentation 28 41 43 56 O
of 42 44 57 59 O
an 45 47 60 62 O
advanced 48 56 63 71 O
solid 57 62 72 77 B-cancer
tumor 63 68 78 83 I-cancer

Patient 0 7 84 91 O
has 8 11 92 95 O
a 12 13 96 97 O
primary 14 21 98 105 B-cancer
neoplasm 22 30 106 114 I-cancer
of 31 33 115 117 I-cancer
the 34 37 118 121 I-cancer
brain 38 43 122 127 I-cancer
or 44 46 128 130 O
known 47 52 131 136 O
uncontrolled 53 65 137 149 O
metastases 66 76 150 160 B-cancer
to 77 79 161 163 I-cancer
the 80 83 164 167 I-cancer
central 84 91 168 175 I-cancer
nervous 92 99 176 183 I-cancer
system 100 106 184 190 I-cancer
( 107 108 191 192 I-cancer
CNS 108 111 192 195 I-cancer
) 111 112 195 196 I-cancer

Patient 0 7 197 204 O
has 8 11 205 208 O
an 12 14 209 211 O
Eastern 15 22 212 219 B-clinical_variable
Cooperative 23 34 220 231 I-clinical_variable
Oncology 35 43 232 240 I-clinical_variable
Group 44 49 241 246 I-clinical_variable
( 50 51 247 248 I-clinical_variable
ECOG 51 55 248 252 I-clinical_variable
) 55 56 252 253 I-clinical_variable
performance 57 68 254 265 I-clinical_variable
status 69 75 266 272 I-clinical_variable
≤ 76 77 273 274 O
1 78 79 275 276 B-upper_bound

Patients 0 8 277 285 O
diagnosed 9 18 286 295 O
with 19 23 296 300 O
another 24 31 301 308 O
primary 32 39 309 316 B-cancer
malignancy 40 50 317 327 I-cancer
within 51 57 328 334 O
3 58 59 335 336 B-upper_bound
years 60 65 337 342 I-upper_bound
prior 66 71 343 348 I-upper_bound
to 72 74 349 351 O
study 75 80 352 357 O
start 81 86 358 363 O

Patients 0 8 364 372 O
who 9 12 373 376 O
have 13 17 377 381 O
received 18 26 382 390 O
prior 27 32 391 396 B-treatment
systemic 33 41 397 405 I-treatment
anticancer 42 52 406 416 I-treatment
therapy 53 60 417 424 I-treatment
≤ 61 62 425 426 O
3 63 64 427 428 B-upper_bound
weeks 65 70 429 434 I-upper_bound
prior 71 76 435 440 I-upper_bound
to 77 79 441 443 O
study 80 85 444 449 O
start 86 91 450 455 O
( 92 93 456 457 O
6 93 94 457 458 O
weeks 95 100 459 464 O
for 101 104 465 468 O
nitrosourea 105 116 469 480 B-treatment
, 116 117 480 481 O
antibodies 118 128 482 492 B-treatment
, 128 129 492 493 O
or 130 132 494 496 O
mitomycin 133 142 497 506 B-treatment
- 142 143 506 507 I-treatment
C 143 144 507 508 I-treatment
) 144 145 508 509 O

Patients 0 8 510 518 O
with 9 13 519 523 O
glioblastoma 14 26 524 536 B-cancer
multiforme 27 37 537 547 I-cancer

Patients 0 8 548 556 O
with 9 13 557 561 O
other 14 19 562 567 O
major 20 25 568 573 O
uncontrolled 26 38 574 586 O
medical 39 46 587 594 O
conditions 47 57 595 605 O
, 57 58 605 606 O
e.g. 59 63 607 611 O
, 63 64 611 612 O
recent 65 71 613 619 O
myocardial 72 82 620 630 B-chronic_disease
infarction 83 93 631 641 I-chronic_disease
, 93 94 641 642 O
stroke 95 101 643 649 B-chronic_disease
, 101 102 649 650 O
diabetes 103 111 651 659 B-chronic_disease
, 111 112 659 660 O
active 113 119 661 667 O
hepatitis 120 129 668 677 B-chronic_disease

Subject 0 7 678 685 O
must 8 12 686 690 O
have 13 17 691 695 O
metastatic 18 28 696 706 O
or 29 31 707 709 O
recurrent 32 41 710 719 O
disease 42 49 720 727 O
and 50 53 728 731 O
have 54 58 732 736 O
failed 59 65 737 743 O
first 66 71 744 749 B-treatment
- 71 72 749 750 I-treatment
line 72 76 750 754 I-treatment
systemic 77 85 755 763 I-treatment
treatment 86 95 764 773 I-treatment
, 95 96 773 774 O
and 97 100 775 778 O
if 101 103 779 781 O
indicated 104 113 782 791 O
, 113 114 791 792 O
failed 115 121 793 799 O
approved 122 130 800 808 O
second 131 137 809 815 B-treatment
- 137 138 815 816 I-treatment
line 138 142 816 820 I-treatment
therapy 143 150 821 828 I-treatment
, 150 151 828 829 O
and 152 155 830 833 O
for 156 159 834 837 O
whom 160 164 838 842 O
no 165 167 843 845 O
standard 168 176 846 854 B-treatment
therapy 177 184 855 862 I-treatment
options 185 192 863 870 O
are 193 196 871 874 O
anticipated 197 208 875 886 O
to 209 211 887 889 O
result 212 218 890 896 O
in 219 221 897 899 O
a 222 223 900 901 O
durable 224 231 902 909 O
remission 232 241 910 919 O

The 0 3 920 923 O
patient 4 11 924 931 O
's 11 13 931 933 O
tumor 14 19 934 939 B-cancer
has 20 23 940 943 O
been 24 28 944 948 O
evaluated 29 38 949 958 O
and 39 42 959 962 O
prospectively 43 56 963 976 O
identified 57 67 977 987 O
as 68 70 988 990 O
having 71 77 991 997 O
FGFR 78 82 998 1002 B-clinical_variable
1 83 84 1003 1004 O
, 84 85 1004 1005 O
2 86 87 1006 1007 O
, 87 88 1007 1008 O
3 89 90 1009 1010 O
, 90 91 1010 1011 O
or 92 94 1012 1014 O
4 95 96 1015 1016 O
genetic 97 104 1017 1024 O
alterations 105 116 1025 1036 O

adequately 0 10 1037 1047 O
treated 11 18 1048 1055 O
basal 19 24 1056 1061 B-cancer
cell 25 29 1062 1066 I-cancer
carcinoma 30 39 1067 1076 I-cancer
, 39 40 1076 1077 O
squamous 41 49 1078 1086 B-cancer
cell 50 54 1087 1091 I-cancer
carcinoma 55 64 1092 1101 I-cancer
, 64 65 1101 1102 O
or 66 68 1103 1105 O
other 69 74 1106 1111 O
non 75 78 1112 1115 B-cancer
- 78 79 1115 1116 I-cancer
melanomatous 79 91 1116 1128 I-cancer
skin 92 96 1129 1133 I-cancer
cancer 97 103 1134 1140 I-cancer
, 103 104 1140 1141 O
or 105 107 1142 1144 O
carcinoma 108 117 1145 1154 B-cancer
in 118 120 1155 1157 I-cancer
situ 121 125 1158 1162 I-cancer
of 126 128 1163 1165 I-cancer
the 129 132 1166 1169 I-cancer
uterine 133 140 1170 1177 I-cancer
cervix 141 147 1178 1184 I-cancer

